Article Versions Notes

Wang S, Huang A, Gu Y, Li J, Huang L, Wang X, Tao Y, Liu Z, Wu C, Yuan Z, et al. Rational Use of Danofloxacin for Treatment of Mycoplasma gallisepticum in Chickens Based on the Clinical Breakpoint and Lung Microbiota Shift. Antibiotics. 2022; 11(3):403. https://doi.org/10.3390/antibiotics11030403

Wang, Shuge, Anxiong Huang, Yufeng Gu, Jun Li, Lingli Huang, Xu Wang, Yanfei Tao, Zhenli Liu, Congming Wu, Zonghui Yuan, and et al. 2022. "Rational Use of Danofloxacin for Treatment of Mycoplasma gallisepticum in Chickens Based on the Clinical Breakpoint and Lung Microbiota Shift" Antibiotics 11, no. 3: 403. https://doi.org/10.3390/antibiotics11030403

Wang, S., Huang, A., Gu, Y., Li, J., Huang, L., Wang, X., Tao, Y., Liu, Z., Wu, C., Yuan, Z., & Hao, H. (2022). Rational Use of Danofloxacin for Treatment of Mycoplasma gallisepticum in Chickens Based on the Clinical Breakpoint and Lung Microbiota Shift. Antibiotics, 11(3), 403. https://doi.org/10.3390/antibiotics11030403